Literature DB >> 24503620

Posttranslational nitro-glycative modifications of albumin in Alzheimer's disease: implications in cytotoxicity and amyloid-β peptide aggregation.

Eva Ramos-Fernández1, Marta Tajes1, Ernest Palomer1, Gerard Ill-Raga1, Mònica Bosch-Morató1, Biuse Guivernau1, Irene Román-Dégano2, Abel Eraso-Pichot1, Daniel Alcolea3, Juan Fortea3, Laura Nuñez4, Antonio Paez4, Francesc Alameda5, Xavier Fernández-Busquets6, Alberto Lleó3, Roberto Elosúa2, Mercé Boada7, Miguel A Valverde1, Francisco J Muñoz1.   

Abstract

Glycation and nitrotyrosination are pathological posttranslational modifications that make proteins prone to losing their physiological properties. Since both modifications are increased in Alzheimer's disease (AD) due to amyloid-β peptide (Aβ) accumulation, we have studied their effect on albumin, the most abundant protein in cerebrospinal fluid and blood. Brain and plasmatic levels of glycated and nitrated albumin were significantly higher in AD patients than in controls. In vitro turbidometry and electron microscopy analyses demonstrated that glycation and nitrotyrosination promote changes in albumin structure and biochemical properties. Glycated albumin was more resistant to proteolysis and less uptake by hepatoma cells occurred. Glycated albumin also reduced the osmolarity expected for a solution containing native albumin. Both glycation and nitrotyrosination turned albumin cytotoxic in a cell type-dependent manner for cerebral and vascular cells. Finally, of particular relevance to AD, these modified albumins were significantly less effective in avoiding Aβ aggregation than native albumin. In summary, nitrotyrosination and especially glycation alter albumin structural and biochemical properties, and these modifications might contribute for the progression of AD.

Entities:  

Keywords:  Albumin; Alzheimer's disease; amyloid; glycation; nitrotyrosination; oxidative stress

Mesh:

Substances:

Year:  2014        PMID: 24503620     DOI: 10.3233/JAD-130914

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  8 in total

Review 1.  Oxidation as an important factor of protein damage: Implications for Maillard reaction.

Authors:  L Trnkova; J Drsata; I Bousova
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

2.  Dietary advanced glycation end products are associated with decline in memory in young elderly.

Authors:  Rebecca K West; Erin Moshier; Irit Lubitz; James Schmeidler; James Godbold; Weijing Cai; Jaime Uribarri; Helen Vlassara; Jeremy M Silverman; Michal Schnaider Beeri
Journal:  Mech Ageing Dev       Date:  2014-07-15       Impact factor: 5.432

Review 3.  Review of methods for detecting glycemic disorders.

Authors:  Michael Bergman; Muhammad Abdul-Ghani; Ralph A DeFronzo; Melania Manco; Giorgio Sesti; Teresa Vanessa Fiorentino; Antonio Ceriello; Mary Rhee; Lawrence S Phillips; Stephanie Chung; Celeste Cravalho; Ram Jagannathan; Louis Monnier; Claude Colette; David Owens; Cristina Bianchi; Stefano Del Prato; Mariana P Monteiro; João Sérgio Neves; Jose Luiz Medina; Maria Paula Macedo; Rogério Tavares Ribeiro; João Filipe Raposo; Brenda Dorcely; Nouran Ibrahim; Martin Buysschaert
Journal:  Diabetes Res Clin Pract       Date:  2020-06-01       Impact factor: 5.602

4.  The antigen-binding fragment of human gamma immunoglobulin prevents amyloid β-peptide folding into β-sheet to form oligomers.

Authors:  Victòria Valls-Comamala; Biuse Guivernau; Jaume Bonet; Marta Puig; Alex Perálvarez-Marín; Ernest Palomer; Xavier Fernàndez-Busquets; Xavier Altafaj; Marta Tajes; Albert Puig-Pijoan; Rubén Vicente; Baldomero Oliva; Francisco J Muñoz
Journal:  Oncotarget       Date:  2017-06-20

5.  Macrophage Migration Inhibitory Factor is subjected to glucose modification and oxidation in Alzheimer's Disease.

Authors:  Omar Kassaar; Marta Pereira Morais; Suying Xu; Emily L Adam; Rosemary C Chamberlain; Bryony Jenkins; Tony D James; Paul T Francis; Stephen Ward; Robert J Williams; Jean van den Elsen
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

6.  Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.

Authors:  Mercè Boada; Oscar L López; Javier Olazarán; Laura Núñez; Michael Pfeffer; Orlando Puente; Gerard Piñol-Ripoll; José E Gámez; Fernando Anaya; Dobri Kiprov; Montserrat Alegret; Carlota Grifols; Miquel Barceló; Jordi Bozzo; Zbigniew M Szczepiorkowski; Antonio Páez
Journal:  Alzheimers Dement       Date:  2021-11-02       Impact factor: 16.655

7.  Inhibitory Effect of Bunium Persicum Hydroalcoholic Extract on Glucose-Induced Albumin Glycation, Oxidation, and Aggregation In Vitro.

Authors:  Arman Seri; Marjan Khorsand; Zahra Rezaei; Azadeh Hamedi; Mohammad Ali Takhshid
Journal:  Iran J Med Sci       Date:  2017-07

8.  AMBAR, an Encouraging Alzheimer's Trial That Raises Questions.

Authors:  David A Loeffler
Journal:  Front Neurol       Date:  2020-05-29       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.